Cardiolipin + Beta2 Glycoprotein 1-IgG + IgM (Phospholipid) Sample Type: Serum

Cardiolipin + Beta-2 Glycoprotein 1 (IgG + IgM) – Phospholipid Antibodies Panel

Sample Type: Serum

Overview:
The Cardiolipin and Beta-2 Glycoprotein 1 (IgG and IgM) test is a part of the antiphospholipid antibody (aPL) panel used to evaluate the presence of antiphospholipid syndrome (APS). APS is an autoimmune disorder associated with recurrent arterial or venous thrombosis and pregnancy complications such as miscarriages or stillbirths.

This test measures IgG and IgM antibodies against two key phospholipid-related targets:

Cardiolipin – a phospholipid found in mitochondrial membranes

Beta-2 Glycoprotein 1 – a plasma protein that binds to cardiolipin and helps regulate clotting

Clinical Significance:
This test is essential in diagnosing or confirming:

Antiphospholipid Syndrome (APS)

Systemic Lupus Erythematosus (SLE) and other autoimmune diseases

Unexplained blood clots (deep vein thrombosis, pulmonary embolism, stroke)

Recurrent pregnancy loss, especially in the second and third trimesters

Test Components:

Cardiolipin IgG and IgM

Beta-2 Glycoprotein 1 IgG and IgM

Interpretation:

Positive Results (moderate to high levels): Suggest a higher risk of thrombosis or pregnancy loss, especially if both IgG and IgM are elevated and confirmed on repeat testing after 12 weeks.

Negative Results: Indicate no significant antiphospholipid antibody activity at the time of testing.

Diagnosis of APS typically requires persistently positive results and clinical symptoms.